Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma
Jen-Jung Pan1, Milind Javle2, Mie Mie Thinn3, Chung-Tzu Hsueh4, Chung-Tsen Hsueh5
1Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, TX, USA; 2Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Division of Oncology, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA; 4Dental Department, Cathay General Hospital, Taipei, Taiwan; 5Division of Medical Oncology and Hematology, Loma Linda University Medical Center, Loma Linda, CA, USA
Abstract: Sorafenib is an oral multiple kinase inhibitor that blocks Raf, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor. It has been approved in the US and Europe for the treatment of advanced hepatocellular carcinoma (HCC). Sorafenib has demonstrated a 44% increase in survival for advanced HCC patients, compared with best supportive care alone. We have reviewed the pharmacology, pivotal studies, and safety data for this agent. Sorafenib is the first systemic drug demonstrating a significant survival benefit, and is the standard of care for patients with advanced HCC for whom no potential curative option is available.
Keywords: sorafenib, hepatocellular carcinoma, multiple kinase inhibitor
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]